Ardelyx Inc. (ARDX)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 5.28 |
Market Cap | 1.19B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.32 |
PE Ratio (ttm) | -15.77 |
Forward PE | n/a |
Analyst | Buy |
Ask | 5.3 |
Volume | 4,623,360 |
Avg. Volume (20D) | 4,900,056 |
Open | 4.88 |
Previous Close | 4.91 |
Day's Range | 4.88 - 5.19 |
52-Week Range | 4.32 - 10.13 |
Beta | undefined |
About ARDX
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult pat...
Analyst Forecast
According to 7 analyst ratings, the average rating for ARDX stock is "Buy." The 12-month stock price forecast is $10.5, which is an increase of 108.13% from the latest price.
Next Earnings Release
Analysts project revenue of $108.57M, reflecting a 215.95% YoY growth and earnings per share of -0.01, making a -91.67% decrease YoY.
Why Price Moved
News
1 month ago · seekingalpha.com
Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save ItArdelyx lost a lawsuit against Medicare, impacting XPHOZAH's revenue potential, with no other major prospects in its pipeline. CMS's decision to move XPHOZAH to the bundled payment system significantl...